RTI Surgical
Global surgical implant company using additive manufacturing to produce Fortilink spinal interbody devices with porous architectures for bone fusion.
- CEO / Founder
- Camille Farhat
- Team Size
- 1001-5000
- Stage
- Acquired
- Total Funding
- $79.8M
- Latest Round
- Acquired
Technology & Products
Key Products
Fortilink spinal interbody systems; Tetrafuse 3D technology; Biologic, metal, and synthetic implants
Technical position · AMPulse analysis
RTI's Fortilink family is produced by additive manufacturing, allowing porous structures that promote bone ingrowth. The Tetrafuse technology is protected by patents and FDA clearances, providing a regulatory barrier to entry.
Differentiation
Value Proposition
3D-printed porous PEEK/titanium spinal implants promote bone ingrowth and fusion, reducing revision rates and improving patient outcomes while enabling faster product innovation.
How They Differentiate
RTI differentiates through its Tetrafuse 3D-printed PEEK technology, which combines the osteoconductive properties of porous titanium with the favorable modulus of PEEK, while competitors focus on titanium-only 3D-printed interbodies.
Market & Competition
Target Customers
Spine surgeons, hospitals, and medical device distributors
Industry Verticals
Medical devices; Spine surgery; Orthopedics
Competitors
Zimmer Biomet (EIT Emerging Implant Technologies); Stryker (Tritanium); Alphatec Holdings
Growth & Milestones
Growth Metrics
Q2 2019 revenue grew 16.4% YoY to $82.31M; full-year 2019 revenue preliminarily reported in January 2020.
Major Milestones
1998: Founded as Regeneration Technologies, Inc.; 2017: Camille Farhat named CEO; 2020: Sold OEM business to Montagu Private Equity for $490M; renamed Surgalign Holdings; 2023: Surgalign filed for Chapter 11 and was acquired by Xtant Medical